Condition
IDH1 Gene Mutation
Total Trials
5
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Active Not Recruiting2
Recruiting1
Unknown1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT04278781Phase 2Active Not Recruiting
AG-120 in People With IDH1 Mutant Chondrosarcoma
NCT03749187Phase 1Active Not Recruiting
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
NCT07007949Phase 2Recruiting
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
NCT03303950Phase 2Terminated
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
NCT04369287Unknown
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia
Showing all 5 trials